[go: up one dir, main page]

ES2422603T3 - Compuestos oxiimino y el uso de estos - Google Patents

Compuestos oxiimino y el uso de estos

Info

Publication number
ES2422603T3
ES2422603T3 ES08767992T ES08767992T ES2422603T3 ES 2422603 T3 ES2422603 T3 ES 2422603T3 ES 08767992 T ES08767992 T ES 08767992T ES 08767992 T ES08767992 T ES 08767992T ES 2422603 T3 ES2422603 T3 ES 2422603T3
Authority
ES
Spain
Prior art keywords
optionally substituted
substituted lower
heterocyclyl
cycloalkenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08767992T
Other languages
English (en)
Inventor
Naoki Tsuno
Hidenori Mikamiyama
Moriyasu Masui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2422603T3 publication Critical patent/ES2422603T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto que tiene la Fórmula I: **Fórmula** una sal o solvato farmacéuticamente aceptable de este, donde: Y es CO o SOm; Z es hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo inferior opcionalmente sustituido, alquiniloinferior opcionalmente sustituido, cicloalquilo opcionalmente sustituido, bicicloalquilo opcionalmente sustituido,cicloalquenilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido,NR5R6, OR5, SR5, COR5 o CONR5R6; R1 y R2 son cada uno independientemente hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo inferioropcionalmente sustituido, alquinilo inferior opcionalmente sustituido, cicloalquilo opcionalmente sustituido,cicloalquenilo opcionalmente sustituido, arilo opcionalmente sustituido, heterociclilo opcionalmente sustituido,ciano, COR5 o CONR5R6, o R1 y R2, considerados conjuntamente con el átomo al que están unidos, forman un cicloalquilo opcionalmentesustituido, bicicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido o heterocicliloopcionalmente sustituido; R5 y R6 son cada uno independientemente hidrógeno, alquilo inferior opcionalmente sustituido, alquenilo inferioropcionalmente sustituido, alquinilo inferior opcionalmente sustituido, cicloalquilo opcionalmente sustituido,bicicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, arilo opcionalmente sustituido oheterociclilo opcionalmente sustituido; cada X es independientemente >=O, alquilo inferior opcionalmente sustituido, alquenilo inferior opcionalmentesustituido, alquinilo inferior opcionalmente sustituido, halógeno, ciano, nitro, NR5R6, OR5, SR5, COR5, COOR5,CONR5R6, NR5COR5, OCOR5, SOR5, SO2R5, SO3R5, SONR5R6, SO2NR5R6, NR5SOR5 o NR5SO2R5;m es 1 o 2. p es 0, 1 o 2; y q es 0 o 1.
ES08767992T 2007-05-31 2008-05-30 Compuestos oxiimino y el uso de estos Active ES2422603T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92480807P 2007-05-31 2007-05-31
PCT/US2008/006888 WO2008150470A1 (en) 2007-05-31 2008-05-30 Oxyimino compounds and the use thereof

Publications (1)

Publication Number Publication Date
ES2422603T3 true ES2422603T3 (es) 2013-09-12

Family

ID=40094014

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08767992T Active ES2422603T3 (es) 2007-05-31 2008-05-30 Compuestos oxiimino y el uso de estos

Country Status (5)

Country Link
US (1) US8563732B2 (es)
EP (1) EP2164325B1 (es)
JP (1) JP5323063B2 (es)
ES (1) ES2422603T3 (es)
WO (1) WO2008150470A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2164326A4 (en) * 2007-05-31 2012-05-09 Euro Celtique Sa AMIDE COMPOUNDS AND USE THEREOF
ES2422603T3 (es) 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
US8518934B2 (en) 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
CN102428069B (zh) * 2009-04-02 2014-04-02 盐野义制药株式会社 丙烯酰胺化合物及其用途
US9090568B2 (en) 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
TWI527800B (zh) 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577441A (en) 1967-03-07 1971-05-04 Warner Lambert Pharmaceutical Nitro substituted benzofurans
HU167365B (es) 1973-11-29 1975-09-27
US4585785A (en) 1979-01-09 1986-04-29 A. H. Robins Company, Inc. Cis and trans-3-aryloxy-4-hydroxypyrrolidines used as anti-arrhythmics
MX6634E (es) 1979-01-09 1985-09-12 Robins Co Inc A H Procedimiento para preparar el isomero trans de 3-ariloxi-4-hidroxipirrolidinas
GB8518869D0 (en) 1985-07-25 1985-08-29 Beecham Group Plc Compounds
EP0210815A3 (en) * 1985-07-25 1988-04-20 Beecham Group Plc 6-beta-(alpha-etherified oxyimino)-acylamino penicillanic-acid derivatives, their preparation and use
GB8908529D0 (en) 1989-04-14 1989-06-01 Merck Sharp & Dohme Therapeutic agents
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5880138A (en) 1996-10-01 1999-03-09 Eli Lilly And Company NMDA receptor selective antagonists
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
KR100609926B1 (ko) 1997-11-12 2006-08-04 다윈 디스커버리 리미티드 엠엠피와 티엔에프 억제 활성을 갖는 히드록삼산 및카르복실산 유도체
TWI222441B (en) 1997-11-26 2004-10-21 Dimensional Pharm Inc Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
UA70976C2 (uk) 1998-12-18 2004-11-15 Аксіз Фармасьютікелз, Інк. (гетеро)арилбіциклічні гетероарильні похідні, їх одержання та використання як інгібіторів протеаз
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002057241A1 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
IL157995A0 (en) 2001-03-20 2004-03-28 Applied Research Systems The use of pyrrolidine ester derivatives in modulation of oxytoxin activity, some new such derivatives, their preparation and pharmaceutical compositions containing them
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
WO2004022535A1 (ja) 2002-08-28 2004-03-18 Yamanouchi Pharmaceutical Co., Ltd. アクリルアミド誘導体
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
CA2527159A1 (en) * 2003-05-30 2004-12-09 Neuromed Technologies, Inc. 3-aminomethyl-pyrrolidines as n-type calcium channel blockers
WO2005068448A1 (en) * 2003-08-29 2005-07-28 Ionix Pharmaceuticals Limited Sulfonamides antagonising n-type calcium channels
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
EP1732566A4 (en) 2004-04-05 2010-01-13 Takeda Pharmaceutical 6-azaindole COMPOUND
JPWO2005105743A1 (ja) 2004-04-28 2008-03-13 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
KR20080015102A (ko) * 2005-05-10 2008-02-18 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
JP4033409B1 (ja) * 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
US8193208B2 (en) 2005-09-09 2012-06-05 Purdue Pharma L.P. Fused and spirocycle compounds and the use thereof
EP1987009A1 (en) 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
CN1850823A (zh) 2006-05-19 2006-10-25 中国科学院上海药物研究所 一类含有肟基的喹诺酮类化合物及其制备方法和用途
TWI372762B (en) 2006-06-23 2012-09-21 Sigma Tau Ind Farmaceuti Amino derivatives of b-homoandrostanes and b-heteroandrostanes
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
ES2422603T3 (es) 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
EP2164326A4 (en) 2007-05-31 2012-05-09 Euro Celtique Sa AMIDE COMPOUNDS AND USE THEREOF
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8518934B2 (en) 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
EP2676956A1 (en) 2008-08-01 2013-12-25 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof

Also Published As

Publication number Publication date
JP5323063B2 (ja) 2013-10-23
EP2164325B1 (en) 2013-04-24
US20100240703A1 (en) 2010-09-23
WO2008150470A1 (en) 2008-12-11
US8563732B2 (en) 2013-10-22
EP2164325A4 (en) 2011-09-14
EP2164325A1 (en) 2010-03-24
JP2010529020A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
ES2422603T3 (es) Compuestos oxiimino y el uso de estos
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
ECSP088479A (es) Derivados de oxadiazol
AR106942A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR078520A1 (es) Compuesto heterociclico y su uso para el control de una plaga de artro-podos
ECSP10010060A (es) Derivados de pirazol sustituídos
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CO6321230A2 (es) Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
ES2678086T3 (es) Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos
EA201070182A1 (ru) Алкилсульфонилзамещённые тиазолидные соединения
AR105340A2 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
ES2662444T3 (es) Derivado de piridina
ES2546851T3 (es) Inhibidores de fosfatidilinositol 3-cinasa
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
AR094621A1 (es) Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
AR085327A1 (es) Inhibidores del virus de la hepatitis c
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR073774A1 (es) Compuestos antibioticos oxazolidinona triciclicos
AR097866A1 (es) Derivados de 4-azaindol
CO6321269A2 (es) Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios
DOP2010000226A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos